Two Sigma Advisers
CBAY

Two Sigma Advisers’s Cymabay Therapeutics CBAY Stock Holding History

Two Sigma Advisers’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-120,200
Closed -$2.84M – 2691
2023
Q4 		$2.84M Sell
120,200
-547,838
-82% -$9.76M 0.01% 1089
2023
Q3 		$9.96M Sell
668,038
-488,400
-42% -$6.47M 0.03% 470
2023
Q2 		$12.7M Sell
1,156,438
-258,400
-18% -$2.41M 0.03% 424
2023
Q1 		$12.3M Buy
1,414,838
+1,011,300
+251% +$8.1M 0.03% 482
2022
Q4 		$2.53M Buy
403,538
+23,700
+6% +$90.1K 0.01% 1111
2022
Q3 		$1.33M Buy
379,838
+232,300
+157% +$834K ﹤0.01% 1377
2022
Q2 		$435K Buy
147,538
+20,500
+16% +$49K ﹤0.01% 1982
2022
Q1 		$395K Sell
127,038
-60,100
-32% -$189K ﹤0.01% 2101
2021
Q4 		$633K Sell
187,138
-196,600
-51% -$746K ﹤0.01% 1797
2021
Q3 		$1.4M Sell
383,738
-464,600
-55% -$1.83M ﹤0.01% 1450
2021
Q2 		$3.7M Sell
848,338
-469,600
-36% -$2.08M 0.01% 1005
2021
Q1 		$5.98M Buy
1,317,938
+102,500
+8% +$552K 0.02% 776
2020
Q4 		$6.98M Buy
1,215,438
+807,300
+198% +$6.11M 0.02% 702
2020
Q3 		$2.96M Buy
408,138
+35,500
+10% +$190K 0.01% 969
2020
Q2 		$1.3M Buy
372,638
+20,400
+6% +$58.9K ﹤0.01% 1449
2020
Q1 		$521K Buy
352,238
+231,000
+191% +$388K ﹤0.01% 1787
2019
Q4 		$238K Buy
+121,238
New +$455K ﹤0.01% 2129
2019
Q2 		– Sell
-21,500
Closed -$286K – 2478
2019
Q1 		$286K Sell
21,500
-2,700
-11% -$28.7K ﹤0.01% 2004
2018
Q4 		$190K Sell
24,200
-14,000
-37% -$133K ﹤0.01% 2142
2018
Q3 		$423K Sell
38,200
-26,400
-41% -$328K ﹤0.01% 1857
2018
Q2 		$867K Sell
64,600
-9,500
-13% -$119K ﹤0.01% 1674
2018
Q1 		$963K Buy
74,100
+59,500
+408% +$739K ﹤0.01% 1560
2017
Q4 		$134K Buy
14,600
+800
+6% +$6.84K ﹤0.01% 2126
2017
Q3 		$111K Buy
+13,800
New +$93.3K ﹤0.01% 2112

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Two Sigma Advisers's CBAY Position: Q1 2024 in Review

Two Sigma Advisers sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 120,200 shares — an estimated $2.84M sold.

Two Sigma Advisers first reported a position in CBAY in Q3 2017 and held it in 24 quarters. The position peaked at $12.7M in Q2 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Two Sigma Advisers reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 120,200 Cymabay Therapeutics shares in Q1 2024, an estimated $2.84M.
  • Two Sigma Advisers first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 24 quarters.
  • Two Sigma Advisers's Cymabay Therapeutics position peaked at $12.7M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Two Sigma Advisers's 13F filing for Q1 2024, filed 15 May 2024.